Meta Platforms
META
Coinbase
COIN
Amazon
AMZN
Apple
AAPL
Oracle
ORCL
US Stock MarketDetailed Quotes
XENE Xenon Pharmaceuticals
- 42.000
- -0.120-0.28%
Close Dec 3 16:00 ET
3.20BMarket Cap-14946P/E (TTM)
42.600High41.570Low290.99KVolume42.000Open42.120Pre Close12.24MTurnover0.41%Turnover RatioLossP/E (Static)76.24MShares50.99052wk High4.01P/B2.96BFloat Cap35.53052wk Low--Dividend TTM70.47MShs Float50.990Historical High--Div YieldTTM2.45%Amplitude2.100Historical Low42.064Avg Price1Lot Size
About Xenon Pharmaceuticals Company
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Company Profile
SymbolXENE
Company NameXenon Pharmaceuticals
Listing DateNov 5, 2014
Issue Price9.00
Founded1996
CEOMr. Ian C. Mortimer
MarketNASDAQ
Employees259
Fiscal Year Ends12-31
Address3650 Gilmore Way,Suite 200
CityBurnaby
ProvinceBritish Columbia
CountryCanada
Zip CodeV5G 4W8
Phone1-604-484-3300
Websitehttp://www.xenon-pharma.com
Company Executives
- Name
- Position
- Salary
- Ian C. Mortimer
- Director, Chief Executive Officer and President
- 9.77M
- Sherry Aulin
- Chief Financial Officer and Principal Accounting Officer
- 3.52M
- Andrea DiFabio
- Chief Legal Officer and Corporate Secretary
- --
- Christopher John Kenney
- Chief Medical Officer
- 3.58M
- Dr. Christopher E. Von Seggern, PhD
- Chief Commercial Officer
- 2.76M
- Dr. Robin Sherrington, PhD
- Executive Vice President, Strategy and Innovation
- 2.37M
- James R. Empfield
- Executive Vice President, Drug Discovery
- --
- Dawn A. Svoronos
- Lead Independent Director
- 588.37K
- Patrick C. Machado, J.D.
- Independent Director
- 559.58K
- Dr. Gillian M. Cannon, PhD
- Independent Director
- 770.91K
- Steven Gannon
- Independent Director
- 561.42K
- Gary Patou, M.D.
- Independent Director
- 560.09K
- Dr. Elizabeth A. Garofalo, M.D.
- Independent Director
- 548.57K
- Justin David Gover
- Independent Director
- 770.91K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.